NEW YORK (GenomeWeb News) – Mount Sinai Services in Toronto and Brigham and Women's Hospital in Boston are collaborating to test Axela's Risk of Recurrence Assay, the company said today.
As part of the collaboration, the two hospitals will conduct a blinded trial of breast cancer patients to assess the ability of the assay to predict the five-year risk of distant metastasis and the ability of cancer center laboratories to use the test locally.
The study will provide information on the risk of recurrence, ER/PR/HER2 status, and molecular subtype, as well as information about the activation levels of the proliferation and immune response pathways on formalin-fixed, paraffin-embedded tumor samples analyzed with the Toronto-based firm's Flow-Thru Chip technology. Results of the study are expected to be completed in the fall and will be used to characterize the assay's performance in the context of other clinical factors being used to manage the treatment of breast cancer patients.
Financial and other terms of the collaboration were not disclosed.